Aurobindo Pharma Limited has informed the Exchange about General Updates

Regulatory & Legal View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.7%Reaction day

₹1289.80

prior close

₹1278.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+1.9%-3.6% vs market

Pharmaceuticals peers, median of 158sector+1.1%-2.8% vs sector

On the reaction day the stock moved 3.6 pts less than Nifty Midcap 150 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.4

15m

+0.9

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.7+1.9-3.6+1.1-2.8

Next day

-2.9-1.3-1.6-0.5-2.4

+0.2-0.7+0.9+0.2-0.0

-0.4-4.5+4.1-3.5+3.0

-0.8-2.1+1.4-2.1+1.3

+1.6+0.2+1.4+0.0+1.6

+0.9-4.6+5.5-5.0+5.9

15d

+3.9+4.0-0.1+5.7-1.9

+5.9+8.1-2.3+8.3-2.4

+16.3+9.0+7.3+10.7+5.6

+12.1+12.4-0.3+15.5-3.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma has informed stock exchanges that the US FDA has classified Unit-II of its wholly owned subsidiary Eugia Pharma Specialities Limited, located in Bhiwadi, Rajasthan, as 'Official Action Indicated' (OAI). The facility was inspected from November 3 to November 14, 2025, and received a Form 483 with 9 observations at the end of the inspection. OAI is the most serious of the FDA's three inspection classifications and typically indicates that regulatory action such as a warning letter or import alert may follow. The company has stated that it does not currently foresee any impact on its business and is committed to maintaining quality standards.

Likely market impact

This is a negative regulatory development that could potentially affect future US supplies from this facility if the FDA escalates to a warning letter or import alert. Investors should watch for further updates, though the company has downplayed the near-term business impact.